NTGN - Neon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.5700
-0.5600 (-13.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.1300
Open4.1100
Bid0.0000 x 800
Ask0.0000 x 1200
Day's Range3.4900 - 4.1541
52 Week Range3.4900 - 13.0000
Volume345,529
Avg. Volume136,428
Market Cap101.143M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire7 days ago

    Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers

    NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical.

  • GlobeNewswire2 months ago

    Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference

    CAMBRIDGE, Mass., June 03, 2019 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced.

  • GlobeNewswire2 months ago

    Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update

    Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics.

  • GlobeNewswire2 months ago

    Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference

    CAMBRIDGE, Mass., May 08, 2019 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced.

  • GlobeNewswire3 months ago

    Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer

    Neon Therapeutics, Inc. (NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the completion of enrollment in NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with KEYTRUDA® (pembrolizumab) and chemotherapy in patients with untreated advanced or metastatic non-small cell lung cancer (NSCLC). “Our NT-002 trial has the potential to demonstrate the effect that NEO-PV-01, our personal neoantigen vaccine, may have in combination with pembrolizumab and chemotherapy, the current standard of care in first-line metastatic NSCLC.

  • GlobeNewswire4 months ago

    Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting

    Neon Therapeutics, Inc. (NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today presented updated data describing the immune and pathologic markers associated with durable clinical benefit in patients enrolled in NT-001, an ongoing Phase 1b clinical trial evaluating NEO-PV-01 in combination with nivolumab (OPDIVO® or anti-PD-1 therapy). The data were highlighted in an oral presentation titled, “The Personalized Vaccine, NEO-PV-01 with Anti-PD-1, Induces Neoantigen-Specific De Novo Immune Responses in Patients with Advanced or Metastatic Melanoma: Association with Clinical Outcomes,” at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta.

  • GlobeNewswire4 months ago

    Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    Neon Therapeutics, Inc. (NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the fourth quarter and full-year ended December 31, 2018 and provided a business update. “2018 was a transformative year for Neon, highlighted by significant advances in applying our insights into neoantigen biology not only to our vaccine product candidates but also to our emerging cellular therapies.  Our initial public offering in June provided us with capital to advance these important programs, which have the potential to truly change the paradigm for immunotherapy by enabling more targeted treatment,” said Hugh O’Dowd, Neon’s Chief Executive Officer. “As we move into 2019, we are excited about the opportunities ahead to share data from our ongoing clinical trials of our personal neoantigen vaccine NEO-PV-01.

  • GlobeNewswire5 months ago

    Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

    CAMBRIDGE, Mass., March 04, 2019 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced.

  • GlobeNewswire5 months ago

    Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting

    CAMBRIDGE, Mass., Feb. 27, 2019 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced.

  • GlobeNewswire5 months ago

    Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference

    CAMBRIDGE, Mass., Feb. 21, 2019 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced.

  • ACCESSWIRE5 months ago

    These 4 Biotech Stocks Are Leading The Industry

    Premier Health Group (PHGRF) (PHGI), Neon Therapeutics Inc (NTGN), Bionano Genomics Inc (BNGO), and XBiotech Inc (XBIT) represent four biotech companies working to champion new treatments for consumers in the space. The Company has magnetized investors looking for opportunities in the biotech sector by strategically investing in products and services that demonstrate Premier's dedication to the industry, as well to patients simply looking for a means of feeling better. Premier Health Group (PHGRF) (PHGI) announced towards the end of last month that, further to itsnew release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • GlobeNewswire7 months ago

    Neon Therapeutics Provides Business Update and Outlook for 2019

    “We have an exciting year ahead of us in 2019, with multiple data readouts from our personal neoantigen vaccine program, NEO-PV-01, in a variety of metastatic cancer settings using a number of rational treatment combinations. “We expect the upcoming data readouts to include correlations between mechanism of action and clinical response and enable development of later-stage trials that will draw on treatment combinations and target patient populations most likely to benefit from our personal cancer vaccine,” said Richard Gaynor, M.D., Neon’s President of Research and Development.

  • GlobeNewswire7 months ago

    Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

    Neon Therapeutics, Inc. (NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, and Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that patient dosing has begun in NT-003, Neon’s Phase 1b combination trial of NEO-PV-01 in metastatic melanoma. The Phase 1b trial is evaluating NEO-PV-01 and nivolumab in combination with other agents in first-line patients with advanced or metastatic melanoma. One arm of the multi-arm study will evaluate the vaccine and nivolumab in combination with Apexigen's APX005M, an investigational CD40 agonist.

  • GlobeNewswire8 months ago

    Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe

    Neon Therapeutics (NTGN) has been named one of the top places to work in Massachusetts by The Boston Globe, an honor awarded based on employee feedback. The Top Places to Work awards recognize the most admired workplaces in the state, as voted on by the employees of those companies. Neon was ranked first among the small biotech companies surveyed and sixth overall among Massachusetts companies with fewer than 100 employees.

  • GlobeNewswire8 months ago

    Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

    Data presented at ESMO and SITC underscore continued clinical progress across platform and pipeline CAMBRIDGE, Mass., Nov. 12, 2018 -- Neon Therapeutics, Inc. (Nasdaq: NTGN),.

  • GlobeNewswire8 months ago

    Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) --  Neon Therapeutics, Inc. (NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today presents updated data from NT-001, its ongoing Phase 1b clinical trial evaluating NEO-PV-01 in the metastatic setting, and new data relating to its NEO-PTC-01 program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting in Washington, D.C. “We are pleased to have Siwen Hu-Lieskovan M.D., Ph.D., a clinical investigator from the David Geffen School of Medicine at the University of California, Los Angeles, present data from our NT-001 Phase 1b study focusing on detailed patient vignettes from the study. For the first time using patient materials, we demonstrate that NEO-STIM™, our proprietary ex vivo co-culture process using peripheral blood mononuclear cells, can reliably and reproducibly generate multiple enriched neoantigen-specific T cell populations that are capable of killing tumor cells.

  • GlobeNewswire8 months ago

    Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors

    Seasoned executive brings more than 20 years of biopharmaceutical industry experience CAMBRIDGE, Mass., Nov. 07, 2018 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a.

  • GlobeNewswire9 months ago

    Neon Therapeutics to Host Investor Event at Society for Immunotherapy of Cancer 33rd Annual Meeting

    CAMBRIDGE, Mass., Nov. 01, 2018 -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced.

  • Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
    PR Newswire9 months ago

    Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine

    Combines Neon's Personal Neoantigen Vaccine and Signatera (RUO) Circulating Tumor DNA Biomarker in Metastatic Non-Small Cell Lung Cancer Trial SAN CARLOS, Calif. , & CAMBRIDGE, Mass. , Oct. 18, 2018 /PRNewswire/ ...